578 related articles for article (PubMed ID: 26974250)
41. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
42. Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology.
Dorton BJ; Vitonis AF; Feldman S
Hum Vaccin Immunother; 2016 Jun; 12(6):1639-45. PubMed ID: 26839185
[TBL] [Abstract][Full Text] [Related]
43. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
44. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
45. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.
Ngabo F; Franceschi S; Baussano I; Umulisa MC; Snijders PJ; Uyterlinde AM; Lazzarato F; Tenet V; Gatera M; Binagwaho A; Clifford GM
BMC Infect Dis; 2016 May; 16():225. PubMed ID: 27221238
[TBL] [Abstract][Full Text] [Related]
46. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
47. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.
Dillner J; Nygård M; Munk C; Hortlund M; Hansen BT; Lagheden C; Liaw KL; Kjaer SK
Vaccine; 2018 Jun; 36(26):3820-3829. PubMed ID: 29778519
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions.
Dehlendorff C; Sparén P; Baldur-Felskov B; Herweijer E; Arnheim-Dahlström L; Ploner A; Uhnoo I; Kjaer SK
Vaccine; 2018 Oct; 36(43):6373-6378. PubMed ID: 30249423
[TBL] [Abstract][Full Text] [Related]
49. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
[TBL] [Abstract][Full Text] [Related]
51. Introduction of a National HPV vaccination program into Bhutan.
Dorji T; Tshomo U; Phuntsho S; Tamang TD; Tshokey T; Baussano I; Franceschi S; Clifford G
Vaccine; 2015 Jul; 33(31):3726-30. PubMed ID: 26057136
[TBL] [Abstract][Full Text] [Related]
52. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
54. The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women.
Nielsen A; Iftner T; Nørgaard M; Munk C; Junge J; Kjaer SK
Sex Transm Infect; 2012 Dec; 88(8):627-32. PubMed ID: 22773328
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
[TBL] [Abstract][Full Text] [Related]
56. Risk factors for cervical neoplasia in Denmark.
Kjaer SK
APMIS Suppl; 1998; 80():1-41. PubMed ID: 9693662
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
58. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
[TBL] [Abstract][Full Text] [Related]
59. Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan.
Ozawa N; Ito K; Tase T; Metoki H; Yaegashi N
Tohoku J Exp Med; 2016 Oct; 240(2):147-151. PubMed ID: 27746423
[TBL] [Abstract][Full Text] [Related]
60. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.
Baldur-Felskov B; Dehlendorff C; Munk C; Kjaer SK
J Natl Cancer Inst; 2014 Mar; 106(3):djt460. PubMed ID: 24552678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
